Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories

Psychological Medicine

Volumn 46, Issue 7, 2016, Pages 1459-1472

  Kishimoto, T ^a,b,c,d   Chawla, J M ^b   Hagi, K ^b,e   Zarate, C A ^f   Kane, J M ^b,c,d   Bauer, M ^g   Correll, C U ^b,c,d  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bipolar depression; depression; ketamine; meta analyses; N methyl d aspartate receptor antagonists; trajectories

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANTAGONISTS AND INHIBITORS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84957943057     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291716000064     Document Type: Article

References (54)

1. Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 67, 139-145.
2. Aan Het Rot M, Zarate CA Jr., Charney DS, Mathew SJ (2012). Ketamine for depression: where do we go from here? Biological Psychiatry 72, 537-547.
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47, 351-354.
4. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). Journal of Traumatic Stress 11, 125-136.
5. Burch RM, Singla N, Parulan C, Burgdorf J (2010). GLYX-13, an NMDA receptor glycine site functional partial agonist, does not elicit psychotomimetic side effects in normal human volunteers at doses expected to be therapeutic in treatment-resistant major depressive disorder. In The 50th Annual Meeting of the National Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, 14-17 June 2010.
6. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2014). Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-Analysis of efficacy. Therapeutic Advances in Psychopharmacology 4, 75-99.
7. Covvey JR, Crawford AN, Lowe DK (2012). Intravenous ketamine for treatment-resistant major depressive disorder. Annals of Pharmacotherapy 46, 117-123.
8. Coyle CM, Laws KR (2015). The use of ketamine as an antidepressant: a systematic review and meta-Analysis. Human Psychopharmacology 30, 152-163.
9. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr. (2010a). A randomized add-on trial of an N-methyl-D-Aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67, 793-802.
10. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr. (2010b). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-Aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 71, 1605-1611.
11. Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L (2014). Ketamine administration in depressive disorders: a systematic review and meta-Analysis. Psychopharmacology 231, 3663-3676.
12. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23, 56-62.
13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928.
14. Higgins JPT, Green S (editors) (2011). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Cochrane Collaboration: London, UK (http://www.cochrane.org/training/cochrane-handbook). Accessed February 2012.
15. Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, Ungvari GS, CorrellCU, Chiu HF, Xue Y, Tian TF,WuAS,MaX,WangG (2016). Single i.v. ketamine augmentation of newly initiated escitalopramformajor depression: results froma randomized, placebo-controlled 4-week study. Psychological Medicine 46, 623-635.
16. Kasper S, Spadone C, Verpillat P, Angst J (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. International Clinical Psychopharmacology 21, 105-110.
17. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: a meta-Analysis of data submitted to the Food and Drug Administration. PLoS Medicine 5, e45.
18. Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, Harper S, Loo CK (2014). Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World Journal of Biological Psychiatry 15, 579-584.
19. Larkin GL, Beautrais AL (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology 14, 1127-1131.
20. Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders 159, 56-61.
21. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate Jr. CA (2009). Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-Aspartate antagonist. Journal of Clinical Psychiatry 70, 1662-1666.
22. Martinowich K, Jimenez DV, Zarate CA Jr., Manji HK (2013). Rapid antidepressant effects: moving right along. Molecular Psychiatry 18, 856-863.
23. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012). Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26, 189-204.
24. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2015). A systematic review and meta-Analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 45, 693-704.
25. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B (2008). A regulatory Apologia-A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. European Neuropsychopharmacology 18, 623-627.
26. Monaghan DT, Larsen H (1997). NR1 and NR2 subunit contributions to N-methyl-D-Aspartate receptor channel blocker pharmacology. Journal of Pharmacology and Experimental Therapeutics 280, 614-620.
27. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry: the Journal of Mental Science 134, 382-389.
28. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, CortinovisM, de Vaccaro KC, CouserW, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Févre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R,Mabweijano J,MacIntyreMF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M,Moran A,Morawska L,Mori R,MurdochME,Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA III, Popova S, Porrini E, Pourmalek F, PrinceM, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De León FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, TonelliM, Towbin JA, Truelsen T, TsilimbarisMK, Ubeda C, Undurraga EA, van derWerfMJ, van Os J, VavilalaMS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA (2012). Disability-Adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2197-2223.
29. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry 170, 1134-1142.
30. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry 74, 250-256.
31. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments (2015). Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. American Journal of Psychiatry 172, 950-966.
32. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 790-812.
33. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry 170, 1249-1262.
34. Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33, 88-109.
35. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM; GLYX-13 Clinical Study Group (2015). Randomized proof of concept trial of GLYX-13, an N-methyl-D-Aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. Journal of Psychiatric Practice 21, 140-149.
36. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-Aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28, 631-637.
37. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ (2014). Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depression and Anxiety 31, 335-343.
38. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry 66, 522-526.
39. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. American Journal of Psychiatry 163, 1905-1917.
40. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine 356, 1711-1722.
41. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC (2014). Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Molecular Psychiatry 19, 978-985.
42. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews. Drug Discovery 7, 426-437.
43. Singh J, Fedgchin M, Daly E, De Boer P, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton G, Kurian B, Winokur A, Fava M, Manji H, Drevets W, Van Nueten L (2014). A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression. In Society of Biological Psychiatry 69th Annual Scientific Meeting, New York, USA, 8-10 May 2014.
44. Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T (2013). Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinology Letters 34, 287-293.
45. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-Analysis of depression, quality of life, and safety outcomes. PLoS Medicine 10, e1001403.
46. Szymkowicz SM, Finnegan N, Dale RM (2013). A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. Journal of Affective Disorders 147, 416-420.
47. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M (2006). Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressant: a critical overview. Pharmacological Reviews 58, 115-134.
48. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358, 252-260.
49. Vieta E, Locklear J, Günther O, Ekman M, Miltenburger C, Chatterton ML, Aström M, Paulsson B (2010). Treatment options for bipolar depression: a systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 30, 579-590.
50. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR (2007). The STAR D project results: a comprehensive review of findings. Current Psychiatry Reports 9, 449-459.
51. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 133, 429-435.
52. Zarate CA Jr., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry 71, 939-946.
53. Zarate CA Jr., Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA (2013). A randomized trial of a low-trapping nonselective N-methyl-D-Aspartate channel blocker in major depression. Biological Psychiatry 74, 257-264.
54. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006). A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.